Roberts Pharmaceutical Corp.

Oct 28, 99
08:00 ET	Roberts Pharmaceutical Corporation Reports Third Quarter Per Share Earnings Of $0.22, Exceeding Analysts Expectations
Sep 08, 99
08:00 ET	Roberts Pharmaceutical Corporation and Orion Corporation Agree on U.S. Rights To Market Fareston, A Treatment for Advanced Breast Cancer
Jul 15, 99
08:00 ET	Roberts Pharmaceutical Corporation Reports Second Quarter Per Share Earnings Of $0.23, Exceeding Consensus Estimates
Jun 23, 99
08:01 ET	Roberts Pharmaceutical Corporation Buys All Rights To Argylin from Bristol-Myers Squibb and Expects Transaction to be Accretive to Earnings
Jun 08, 99
08:03 ET	Roberts Pharmaceutical Corporation Receives Orphan Drug Status for Agrylin In Japan
Jun 02, 99
08:00 ET	Roberts Pharmaceutical Corporation Announces Election of Ronald M. Nordmann to its Board of Directors
May 11, 99
07:59 ET	Roberts Pharmaceutical Corporation Forms Strategic Alliance With Gynetics Inc. For Canadian Marketing of PREVEN(TM), the Emergency Contraceptive Kit
May 05, 99
08:00 ET	Roberts Pharmaceutical Corporation to Market Amatine in Canada
Apr 28, 99
08:00 ET	Roberts Pharmaceutical Corporation Reports Strong First Quarter Results;
Mar 16, 99
08:00 ET	Roberts Pharmaceutical Corporation Reports Phase III Data Indicate Strong Analgesic Potency of Dirame(R)
Mar 09, 99
08:01 ET	Roberts Pharmaceutical Corporation Acquires Lodine, a Selective C0X-2 Inhibitor, for the United Kingdom and Republic of Ireland
Feb 17, 99
08:00 ET	Roberts Pharmaceutical Corporation Reports Record Fourth Quarter and Full Year 1998 Revenues with Per Share Earnings Exceeding Estimates
Feb 08, 99
08:30 ET	Roberts Pharmaceutical Corporation In Late-Stage Development of A Long-Duration LHRH-Implant For Prostate Cancer
Feb 01, 99
08:30 ET	Roberts Pharmaceutical Corporation Announces Distribution Agreement for Agrylin in Korea
Jan 15, 99
08:30 ET	Roberts Pharmaceutical Corporation Tells Investment Managers that the Company is Optimistic about Its Growth Prospects
Dec 21, 98
08:00 ET	Roberts Pharmaceutical Corporation Announces FDA Clears Agrylin For a Broader Patient Population
Nov 02, 98
08:31 ET	Roberts Pharmaceutical Corporation Provides Expanded Online Information and Services
Oct 22, 98
08:37 ET	Roberts Pharmaceutical Corporation Reports a 49% Increase in Third Quarter Revenues With Per Share Earnings Ahead of Estimates
Oct 12, 98
07:30 ET	Roberts Pharmaceutical Corporation Anticipates Reporting a Third Quarter Profit Exceeding Expectations
Sep 22, 98
08:30 ET	Roberts Pharmaceutical Corporation Announces Decision of Its Founder to Retire
Aug 27, 98
08:00 ET	Roberts Pharmaceutical Corporation Announces Election of Joseph E. Smith to its Board of Directors
Jul 29, 98
08:30 ET	Roberts Pharmaceutical Corporation Receives Israeli Approval for its New Drug Agrylin
Jul 21, 98
07:30 ET	Roberts Pharmaceutical Corporation Reports Strong Second-Quarter Results With Per Share Earnings Exceeding Analyst Estimates
Jul 07, 98
09:01 ET	Roberts Pharmaceutical Corporation and Ribogene in Agreement for Development of Phase III Intranasal Drug for Chemotherapy Induced Emesis
Jun 26, 98
10:00 ET	Roberts Pharmaceutical Corporation Announces Financing Agreement with a Syndicate of Institutional Investors and Banks
Jun 16, 98
09:53 ET	Roberts Pharmaceutical Corporation in Agreement to Out-License a Pipeline Compound to Adolor Corporation
Jun 10, 98
08:01 ET	Roberts Pharmaceutical Corporation Receives Patent to Year 2017 for New Process to Manufacture its Drug Agrylin
May 20, 98
10:59 ET	Roberts Pharmaceutical Corporation Announces Management Additions and the Creation of Separate U.S. Prescription and Consumer Products Divisions
Apr 29, 98
07:58 ET	Roberts Pharmaceutical Corporation Reports a 25% Increase in First-Quarter 1998 Revenues and a Strong Improvement in Per Share Earnings to $0.07.
Apr 27, 98
13:15 ET	Roberts Pharmaceutical Corporation Announces Sale of VRG International, A Contract Research Business; Expects First-Quarter Earnings to Exceed Estimates
Apr 16, 98
07:28 ET	Roberts Pharmaceutical Acquires Exclusive U.S. Rights To Market Pentasa From Hoechst Marion Roussel
Feb 18, 98
07:45 ET	Roberts Pharmaceutical Corporation Reports Strong Improvement in Operating Performance With Fourth Quarter 1997 Net Profits of $0.11 Per Share
Jan 20, 98
07:45 ET	Roberts Pharmaceutical Corporation Expects to Report A Fourth Quarter 1997 Profit Significantly Exceeding Analyst Estimates
Jan 08, 98
11:56 ET	Roberts Pharmaceutical Corporation Submits Regulatory Applications to Broaden the Marketing Potential of Its Two New Drugs Agrylin and ProAmatine
Dec 17, 97
07:30 ET	Roberts Pharmaceutical Corporation Announces A Product Transaction Agreement With G.D. Searle
Nov 24, 97
08:15 ET	Roberts Pharmaceutical Corporation Receives Canadian Approval For Its New Drug Agrylin
Nov 10, 97
07:30 ET	Roberts Pharmaceutical Corporation Completes Phase 1a Study of Ly315535 For Functional Bowel Disorders
Nov 05, 97
08:00 ET	Roberts Pharm. Corp. Announces Mgmt. Addition to the Newly Created Position of Sr. Vice President, New Business Development and Strategic Planning
Oct 20, 97
07:29 ET	Roberts Pharmaceutical Corporation Reports Third Quarter 1997 Results in Line with Expectations
Sep 18, 97
16:01 ET	Roberts Pharmaceutical Corporation Updates Third Quarter Outlook
Sep 11, 97
07:30 ET	Founder and CEO of Roberts Pharmaceutical Corporation Announces Changes in Management Structure
Jul 31, 97
16:06 ET	Roberts Pharmaceutical Corporation Announces Agreement in Principle to Settle Class Action Lawsuit - Continued Profitability Expected -
Jul 23, 97
09:49 ET	Roberts Pharmaceutical Corporation Completes FDA Filing of IND to Develop Drug for Large, Unsatisfied Gastrointestinal Market
Jul 22, 97
12:00 ET	Roberts Pharmaceutical Corporation Comments on Stock Price Activity
Jul 17, 97
07:33 ET	Roberts Pharmaceutical Corporation Reports Third Consecutive Profitable Quarter
Jul 09, 97
07:46 ET	Roberts Pharmaceutical Corporation Files for European Approval of its New Drug Agrylin
Jul 07, 97
08:02 ET	Roberts Pharmaceutical Corporation Completes Acquisition of Searle Manufacturing Facility
May 21, 97
14:56 ET	Roberts Pharmaceutical Corporation Announces New Members of Board of Directors
10:00 ET	Roberts Pharmaceutical Corporation To Begin Trading On The American Stock Exchange Effective May 22, 1997
Apr 16, 97
07:29 ET	Roberts Pharmaceutical Corporation Reports First Quarter 1997 Profit And A 53% Year-To-Year Advance In Revenues
Apr 10, 97
07:29 ET	Roberts Pharmaceutical Corporation Announces Management Addition to Newly Created Position of Senior Vice President, Medical and Regulatory Affairs
Apr 02, 97
11:30 ET	Roberts Pharmaceutical Corporation Revises 1996 EPS Calculation to Conform with New SEC Guidelines; No Impact on Reported Net Income or Balance Sheet
07:29 ET	Roberts Pharmaceutical Corporation Receives Exclusive License from Pfizer Inc. to Develop Novel New Compound for Large Cardiovascular Market
Mar 17, 97
07:29 ET	Roberts Pharmaceutical Corporation Receives FDA Marketing Approval For Its New Drug AGRYLIN
Mar 06, 97
07:30 ET	Roberts Pharmaceutical Corporation Announces Priority Review Status in Canada For Its New Drug Agrylin And Plans to File This Year For European Approval
Mar 03, 97
15:25 ET	A Letter from the Chairman of the Board of Roberts Pharmaceutical Corp.
Feb 18, 97
07:00 ET	Roberts Pharmaceutical Corporation Reports Fourth Quarter 1996 Profit From Operations
Feb 03, 97
09:45 ET	Roberts Pharmaceutical Corporation Receives FDA Approvable Letter For AGRYLIN Drug Targets A Therapeutic Void
Jan 21, 97
07:29 ET	Roberts Pharmaceutical Corporation Expects Fourth Quarter 1996 Operating Results to Exceed Analyst Projections
Jan 06, 97
07:30 ET	Roberts Pharmaceutical Corporation Receives License from Wyeth Laboratories To Market Lodine in the U.K. and Ireland
Dec 23, 96
07:30 ET	Roberts Pharmaceutical Corporation Adopts Shareholder Rights Plan
Dec 05, 96
07:30 ET	Roberts Pharmaceutical Corporation and Eli Lilly and Company to Expand Agreement for Compounds in Development for Large Gastrointestinal Market
Nov 27, 96
08:00 ET	Roberts Pharmaceutical Corporation Comments on Stock Price Activity
Nov 15, 96
07:00 ET	Roberts Pharmaceuticals Corporation Reports Third Quarter 1996 Results Reflect Transition Toward Commercialization Of Pipeline Drugs
Nov 08, 96
10:07 ET	Roberts Pharmaceutical Corporation Concludes Special Shareholders Meeting and Also Notes FDA Labeling Review of Agrelin in Progress
Nov 06, 96
08:50 ET	Roberts Pharmaceutical Corporation To License Gastrointestinal Compounds from Eli Lilly and Company
Oct 15, 96
10:30 ET	Roberts Pharmaceutical Corporation to Acquire Searle's FDA/HPB Approved Manufacturing Facility From Monsanto Canada Inc.
Oct 07, 96
13:32 ET	Roberts Pharmaceutical Corporation Elects Zola P. Horovitz to Board of Directors
Oct 03, 96
08:00 ET	Roberts Pharmaceutical Corporation Announces the Sale of Two Product Lines to Monarch Pharmaceuticals
Sep 09, 96
07:30 ET	Roberts Pharmaceutical Corporation Concludes $115 Million Equity Placements
07:00 ET	Roberts Pharmaceutical Corporation Receives FDA Clearance to Launch ProAmatine, the Company's First Pipeline Drug for the U.S. Market
Aug 13, 96
12:22 ET	Roberts Pharmaceutical Corporation Reports Second Quarter Results Substantially Improved From First Quarter 1996 Results
Jul 24, 96
16:39 ET	ROBERTS PHARMACEUTICAL CORPORATION PREPARES CANADIAN LAUNCH OF ADVANTAGE 24;
Jul 22, 96
16:37 ET	ROBERTS PHARMACEUTICAL CORPORATION RECEIVES CANADIAN APPROVAL FOR THE CARDIOVASCULAR DRUG EMINASE
Jul 18, 96
18:34 ET	ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES THE ELECTION OF JOHN T. SPITZNAGEL TO ROBERTS BOARD OF DIRECTORS
16:35 ET	ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES THE ELECTION OF JOHN T. SPITZNAGEL TO ROBERTS BOARD OF DIRECTORS